

ACCELERATED DISTRIBUTION DEMONSTRATION SYSTEM

REGULATORY INFORMATION DISTRIBUTION SYSTEM (RIDS)

ACCESSION NBR:9104020215 DOC.DATE: 91/03/26 NOTARIZED: NO DOCKET #

FACIL:50-269	Oconee Nuclear Station, Unit 1, Duke Power Co.	05000269
50-270	Oconee Nuclear Station, Unit 2, Duke Power Co.	05000270
50-287	Oconee Nuclear Station, Unit 3, Duke Power Co.	05000287
50-369	William B. McGuire Nuclear Station, Unit 1, Duke Powe	05000369
50-370	William B. McGuire Nuclear Station, Unit 2, Duke Powe	05000370
50-413	Catawba Nuclear Station, Unit 1, Duke Power Co.	05000413
50-414	Catawba Nuclear Station, Unit 2, Duke Power Co.	05000414

AUTH.NAME	AUTHOR AFFILIATION
TUCKMAN, M.S.	Duke Power Co.
RECIP.NAME	RECIPIENT AFFILIATION
	Document Control Branch (Document Control Desk)

SUBJECT: Forwards rept summarizing false negative blind performance urine drug screen which occurred during Feb 1991. Filing rept on behalf of B&W.

DISTRIBUTION CODE: A022D COPIES RECEIVED: LTR 1 ENCL 1 SIZE: 6
 TITLE: Fitness for Duty Program: Blind Performance Test/Other

NOTES: LPDR 2cys AMDTS to FSAR. ASLB 1cy.	05000413
LPDR 2cys AMDTS to FSAR. ASLB 1cy.	05000414

	RECIPIENT ID CODE/NAME	COPIES LTR ENCL	RECIPIENT ID CODE/NAME	COPIES LTR ENCL
	PD2-3 LA	1 1	PD2-3 PD	1 1
	WIENS, L	1 1	REED, T	1 1
	MARTIN, R	1 1		
INTERNAL:	ACRS	1 1	NRR/DRIS/RSGB	1 1
	NUDOCS-ABSTRACT	1 1	REG FILE 01	1 1
	RGN2 . 02	1 1		
EXTERNAL:	NRC PDR	1 1	NSIC	1 1
NOTES:		3 3		

NOTE TO ALL "RIDS" RECIPIENTS:

PLEASE HELP US TO REDUCE WASTE! CONTACT THE DOCUMENT CONTROL DESK, ROOM P1-37 (EXT. 20079) TO ELIMINATE YOUR NAME FROM DISTRIBUTION LISTS FOR DOCUMENTS YOU DON'T NEED!

TOTAL NUMBER OF COPIES REQUIRED: LTR 15 ENCL 15

MA
[Handwritten signature]

R
I
D
S
/
A
D
D
S
R
I
D
S
/
A
D
D
S

Duke Power Company
Nuclear Production Dept.
P.O. Box 1007
Charlotte, N.C. 28201-1007

M.S. TUCKMAN
Vice President
Nuclear Operations
(704)373-3851



DUKE POWER

March 26, 1991

U.S. Nuclear Regulatory Commission
ATTN: Document Control Desk
Washington, D.C. 20555

Subject: False Negative, Blind Performance
Urine Drug Screen Report
Oconee Nuclear Station, Docket Nos. 50-269, -270, -287
McGuire Nuclear Station, Docket Nos. 50-369, -370
Catawba Nuclear Station, Docket Nos. 50-413, -414

Gentlemen:

Pursuant to 10 CFR 26, App. A 2.8 (E)(4) find attached the subject report which summarizes Duke Power Company's findings concerning a false negative blind performance urine drug screen which occurred during February 1991. Duke Power Company has approved Babcock and Wilcox's pre-access testing program and is filing this report on behalf of Babcock and Wilcox.

Should there be any questions concerning this matter, contact William E. Dukes, Jr., M.D. at (704) 373-5459.

Very truly yours,

M.S. Tuckman
M.S. Tuckman

JAR/fn

Attachment

xc: Mr. S. D. Ebnetter
Regional Administrator, Region II
U.S. Nuclear Regulatory Commission
101 Marietta St., NW., Suite 2900
Atlanta, Georgia 30323

9104020215 910326
PDR ADOCK 05000269
PDR

A022
111

Document Control Desk
March 26, 1991
Page 2

bxc: W.E. Dukes -WC08C
S.P. Murdock - PB04B
R.M. Bisanar - PB05E
GS-801.01



B&W NUCLEAR SERVICE COMPANY
Special Products & Inspection Services Division

3110 Odd Fellows Road
Lynchburg, VA 24501-5010
Telephone: 804-847-3700
Telecopy: 804-847-1020

March 7, 1991
FAC91015

Ms. Sue P. Murdock, Manager
Nuclear Access and Fitness For Duty
Duke Power Company
422 South Church Street
Charlotte, NC 28242

Dear Sue,

Per our telephone conversation today, I am sending you a copy of the letter from CompuChem which documents a report of a "false negative" on a blind specimen that was sent to CompuChem Laboratories for analysis. I am sending you a copy of the above referenced letter as required by B&W Nuclear Technologies Drug and Alcohol Testing Procedure To Meet The Requirements of 10CFR26 Appendix A

On March 6, 1991 Mr. Ray Marchman and I went to CompuChem Laboratories and did a follow up investigation of the unacceptable results on the blind specimen which was submitted to the laboratory for analysis. We talked to E. Dale Hart, Assistant Director, Technical Programs Forensic Drug Testing Laboratory at CompuChem Laboratories. A discussion was held of what happened, possible causes, and what they were doing to help prevent this from happening again. After these discussions and a review of the laboratory techniques, I feel that they continue to provide us with dependable and reliable services.

If I can answer any additional questions on this matter, please do not hesitate to call me at 804-847-3355.

Very Truly Yours,

F. A. Currence, Manager
BWNT Access Control

enclosures

cc: J. F. Cuvelier
R. T. Marchman



**COMPUCHEM
LABORATORIES, INC.**

P.O. Box 12652 3308 Chapel Hill/Nelson Highway Research Triangle Park, NC 27709 (919) 549-8263

March 5, 1991

B & W Nuclear Technologies
ATTN: Ray Marchman
3110 Odd Fellows Rd.
Lynchburg, VA 24501

Dear Mr. Marchman:

On February 27, 1991, CompuChem Laboratories received a urine sample from B & W Nuclear Technologies (B & W) identified as Social Security Number: 422-87-4156 for forensic drug testing. The sample was assigned an internal accession number of 34404830 and subjected to our standard drug testing protocol in which it screened negative and was reported as such.

Subsequently, we were informed by you that the sample was a proficiency sample with a target concentration (from the preparer/vendor) of 267 ng/mL.

On March 1, the sample was retested per your request. The sample was assigned an internal accession number of 34501106 for the retest. In the retest procedures, the sample screened and confirmed positive for the presence of THC metabolite.

The results of the tests performed on the sample were as follows:

Original Test (THC Screening Cutoff = 20 ng/ml)

EMIT Results in milliabsorbance units (mAU):

<u>Negative</u>	<u>Cutoff</u>	<u>Blind Positive</u>	<u>B & W Sample</u>
965	1066	1076 (+10)	1064 (-2)

Retest

EMIT Results:

<u>Negative</u>	<u>Cutoff</u>	<u>Blind Positive</u>	<u>B & W Sample</u>
871	961	993 (+32)	1016 (+55)

GC/MS Results: 222 ng/mL THC metabolite

Obviously, based upon the results of the retest analyses, the sample should have tested positive in the original test.

One noteworthy observation in the data from the first test is the response difference of 10 mAU between the calibrator (20 ng/mL) and the blind positive control (125 ng/mL). Normally, the response difference between these two samples is on the order of 40-70 mAU. Still, even with the



relatively low response for the blind positive control, one would expect a sample at over 200 ng/mL to give a response greater than a 125 ng/mL control and certainly greater than a 20 ng/mL calibrator.

In my opinion, the original results for the sample in question may have been due to a high calibrator response and a random sampling error in the analysis of the B & W sample. As I mentioned earlier, the normal difference in response between the positive control and the calibrator is approximately 40-70 mAU. Differences outside this range are generally due to statistical variation in the calibration process. Differences less than 40 mAU are due to high calibrator responses, while differences greater than 70 mAU are due to low calibrator responses. In the original test of the sample, a high calibrator response resulted in very little difference between the 20 ng/mL calibrator and the 125 ng/mL blind positive control as well as open controls at the same concentration.

Typically, the variation in EMIT results when a sample is run repeatedly is approximately ± 10 mAU; however, random variations of as much as ± 50 mAU are observed. The greatest source of variability in EMIT procedures run on automated analyzers is the sampling of urine by the instrument. In the sampling process, an instrument probe removes 15 μ L of urine for analysis from a 3 mL total volume of sample contained in a test tube. Errors in this process will lead to analytical variation. When a sampling error is combined with high calibration results, even samples well above the assay cutoff may give results which are below the cutoff.

Unfortunately, random variations in sampling by the instrument are not easily detected. This is because such observations may not occur with the quality control samples run with each group of samples. All that we can do to minimize this type of sampling error is to maintain strict instrument maintenance requirements. Daily maintenance of the instruments is performed to reduce the possibility of such an error.

The problem of high calibrator response leading to decreases in assay resolution can be addressed through changes in our QC requirements for the EMIT procedures. We are in the process of developing minimum separation requirements for EMIT procedures based upon normal performance for each drug parameter. Under these requirements, if controls give responses which are closer to the calibrator than predicted by historical data, the instrument will be recalibrated and samples near the cutoff will be repeated.



COMPUCHEM
LABORATORIES, INC.

If you require any further information regarding the analysis of the sample in question, please phone me at (919) 248 6804.

Respectfully yours,

Edwin D. Hart
Assistant Director,
FDT Technical Programs

cc: Ms. Wanda Boone
Mr. James McCarthy
Mr. Robert Meierer
Dr. Michael Peat

Docket No. 50-413, 50-414
50-369, 50-370
50-269, 50-270, 50-287

MAR 21 1991

Mr. M. S. Tuckman, Vice President
Nuclear Operations
Duke Power Company
P.O. Box 1007
Charlotte, North Carolina 28201-1007

Dear Mr. Tuckman:

SUBJECT: OPERATIONAL EVENTS WHILE SHUTDOWN

The NRC has just issued Information Notice 91-22, "Four Plant Outage Events Involving Loss of AC Power or Coolant Spills," which addresses recent events that occurred during shutdown operations.

The chief purpose of this information notice is to notify each licensee that the high rate of precursor events to loss of decay heat removal during shutdown is a source of concern to the NRC. All of the events discussed in this information notice occurred during a one-week period in March 1991. Because of the potential for loss of a critical safety function in these and similar events, I believe a high level of management attention is required in the planning, coordination, and execution of shutdown operations.

While this information notice does not require specific licensee action or response, I urge you to give this important matter your personal attention.

Sincerely,
Original signed by
Thomas E. Murley

Thomas E. Murley, Director
Office of Nuclear Reactor Regulation

cc: See Next Page

Distribution

Docket File E. Jordan MNBB-3302
PDII-3 R/F ACRS P-315

~~S. Wang~~
R. Martin
T. Reed
L. Wiens
B. Clayton

OFC LA:PDII-3
NAME BC:clayton
DATE 3/20/91

D:NR
TMurley
// 791

OFFICIAL RECORD COPY
Document Name: DUKE PD23 LTR UTILITIES

NRC FILE CENTER COPY

Duke Power Company

Catawba Nuclear Station
McGuire Nuclear Station
Oconee Nuclear Station

cc:

Mr. A.V. Carr, Esq.
Duke Power Company
422 South Church Street
Charlotte, North Carolina 28242-0001

J. Michael McGarry, III, Esq.
Winston and Strawn
1400 L Street, N.W.
Washington, DC 20005

North Carolina MPA-1
Suite 600
P.O. Box 29513
Raleigh, North Carolina 27626-0513

Mr. Frank Modrak
Project Manager, Mid-South Area
ESSD Projects
Westinghouse Electric Corp.
MNC West Tower - Bay 241
P.O. Box 355
Pittsburgh, Pennsylvania 15230

County Manager of York County
York County Courthouse
York, South Carolina 29745

Richard P. Wilson, Esq.
Assistant Attorney General
S.C. Attorney General's Office
P.O. Box 11549
Columbia, South Carolina 29211

Piedmont Municipal Power Agency
121 Village Drive
Greer, South Carolina 29651

Mr. Alan R. Herdt, Chief
Project Branch #3
U.S. Nuclear Regulatory Commission
101 Marietta Street, N.W., Suite 2900
Atlanta, Georgia 30323

North Carolina Electric Membership
P.O. Box 27306
Raleigh, North Carolina 27611

Saluda River Electric Cooperative,
Inc.
P.O. Box 929
Laurens, South Carolina 29360

Senior Resident Inspector
Route 2, Box 179N
York, South Carolina 29745

Regional Administrator, Region II
U.S. Nuclear Regulatory Commission
101 Marietta Street, N.W., Suite 2900
Atlanta, Georgia 30323

Mr. Heyward G. Shealy, Chief
Bureau of Radiological Health
South Carolina Department of Health
and Environmental Control
2600 Bull Street
Columbia, South Carolina 29201

Ms. Karen E. Long
Assistant Attorney General
N.C. Department of Justice
P.O. Box 692
Raleigh, North Carolina 27602

Mr. Robert G. Morgan
Nuclear Production Department
Duke Power Company
P.O. Box 1007
Charlotte, North Carolina 28201-1007

Dr. John M. Barry
Department of Environmental Health
Mecklenburg County
1200 Blythe Boulevard
Charlotte, North Carolina 28203

Duke Power Company

- 2 -

cc:

County Manager of Mecklenburg County
720 East Fourth Street
Charlotte, North Carolina 28202

Honorable James M. Phinney
County Supervisor of Oconee County
Walhalla, South Carolina 29621

Mr. Stephen Benesole
Duke Power Company
P.O. Box 1007
Charlotte, North Carolina 28201-1007

Mr. R.L. Gill, Jr.
Nuclear Production Department
Duke Power Company
P.O. Box 1007
Charlotte, North Carolina 28201-1007

Senior Resident Inspector
c/o U.S. Nuclear Regulatory Commission
12700 Hagers Ferry Road
Huntersville, North Carolina 28078

Office of Intergovernmental Relations
116 West Jones Street
Raleigh, North Carolina 27603

Senior Resident Inspector
U.S. Nuclear Regulatory Commission
Route 2, Box 610
Seneca, South Carolina 27611-7687

Mr. Dayne H. Brown, Director
Department of Environmental,
Health and Natural Resources
Division of Radiation Protection
P.O. Box 27687
Raleigh, North Carolina 27611-7687

Mr. Robert B. Borsum
Babcock & Wilcox
Nuclear Power Division
Suite 525
1700 Rockville Pike
Rockville, Maryland 20852

Manager, LIS
NUS Corporation
2650 McCormick Drive
Clearwater, Florida 34619-1035

Mr. Paul Guill
Duke Power Company
Nuclear Production Department
P.O. Box 1007
Charlotte, North Carolina 28201-1007